FF301 本月底法定/註冊股本總額： RMB 383,568,500 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 重新提交 致：香港交易及結算所有限公司 公司名稱: 北京市春立正達醫療器械股份有限公司 呈交日期: 2026年2月26日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01858 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 95,140,500 | RMB | | 1 | RMB | | 95,140,500 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 95,140,500 | RMB | ...

Group 1 - The core viewpoint of the news highlights the trading performance and financing activities of Spring Medical, indicating a net financing purchase of 271.09 million yuan on February 25, with a total financing and securities balance of 73.01 million yuan [1] - Spring Medical's financing balance of 73.01 million yuan accounts for 1.14% of its circulating market value, which is above the 90th percentile level over the past year, indicating a high level of financing activity [1] - The company has not engaged in any short selling activities on February 25, with a short selling balance of 4458.00 yuan, which is also above the 70th percentile level over the past year, suggesting a relatively high level of short selling interest [1] Group 2 - Spring Medical, established on February 12, 1998, specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [2] - The company reported a revenue of 756 million yuan for the period from January to September 2025, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, reflecting a significant increase of 213.21% year-on-year [2] - As of September 30, 2025, the number of shareholders increased by 4.12% to 6164, while the average circulating shares per person decreased by 3.95% to 46906 shares [2] Group 3 - Spring Medical has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan distributed over the past three years [3] - Among the top ten circulating shareholders as of September 30, 2025, Hong Kong Central Clearing Limited is the fourth largest new shareholder with 2.9585 million shares, while China Europe Economic Selection Mixed A and Ping An Low Carbon Economy Mixed A are also notable new shareholders [3] - South Pharmaceutical Health Flexible Allocation Mixed A has exited the list of the top ten circulating shareholders [3]

Group 1 - The core viewpoint of the news is that Spring Medical has shown significant financial performance with a notable increase in revenue and net profit, indicating strong growth potential in the orthopedic medical device sector [2][3]. - As of February 24, Spring Medical's stock price increased by 0.58%, with a trading volume of 34.10 million yuan, and a net financing purchase of 11.70 million yuan, reflecting active investor interest [1]. - The company's financing balance reached 70.30 million yuan, accounting for 1.09% of its market capitalization, which is above the 90th percentile of the past year, indicating a high level of investor engagement [1]. Group 2 - Spring Medical specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prostheses and spinal implants, which are exported to various regions worldwide [2]. - For the period from January to September 2025, Spring Medical reported a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit of 192 million yuan, which is a 213.21% increase compared to the previous year [2]. - The company has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan distributed over the past three years, indicating a commitment to returning value to shareholders [3].

Core Viewpoint - Spring Medical announced a significant increase in its 2025 annual performance, with a projected net profit growth of 96.01% to 130.41 million and a non-recurring net profit growth of 142.80% to 185.11 million, but the stock price has been declining due to the market's anticipation of this growth being already priced in [1][2] Stock Performance - Spring Medical's stock has shown weakness, with a maximum fluctuation of over 30% since reaching a high of 20.49 HKD in November 2025, dropping to a new low of 13.47 HKD by February 12, 2026 [1] - As of February 23, 2026, the stock price was 13.59 HKD, reflecting a slight increase of 0.07%, but a cumulative decline of 2.72% over the past five days [1] - In the past 60 days, net selling by Hong Kong Stock Connect has totaled 4.054 million shares, reducing the holding ratio from 47.77% in December 2025 to 43.16% in February 2026, resulting in a loss of over 10% [1] - The latest closing price in the A-share market was 22.27 CNY on February 13, 2026, with a daily increase of 0.68%, but a cumulative decline of 15.80% over the past 20 days [1] Financial Performance - The projected increase in 2025 performance is primarily driven by the release of growth potential in product lines post-collective procurement and the advancement of international business [2] - The significant growth in non-recurring net profit compared to net profit indicates an improvement in core business operations [2] - For the first three quarters of 2025, revenue reached 755.6 million CNY, representing a growth of 48.75%, while net profit attributable to shareholders was 192 million CNY, reflecting a substantial increase of 213.21% [2] - The international business has shown remarkable progress, with overseas revenue accounting for 40% of total revenue, shifting market focus towards the potential of overseas expansion as a key factor for stock price recovery [2]

Core Viewpoint - Spring Medical (01858) has announced a significant increase in its expected net profit for the fiscal year 2025, with projections indicating a rise of 96.01% to 130.41% year-on-year, driven by improvements in its core business and international expansion efforts [1][4]. Financial Performance - The company anticipates a net profit attributable to shareholders of between 245 million to 288 million yuan, and a non-recurring net profit of 230 million to 270 million yuan, reflecting increases of 96.01% to 130.41% and 142.80% to 185.11% respectively [1][4]. - In Q1 of the previous year, Spring Medical reported a revenue of 230 million yuan, marking a 3.6% increase, and a net profit of 58 million yuan, up 5.2% [7]. - By Q3 of the previous year, the company achieved a revenue of 756 million yuan, a year-on-year growth of 48.75%, and a net profit of 192 million yuan, a significant increase of 213.21% [7]. Market Reaction - Despite the positive earnings forecast, the market response was muted, with the stock price dropping by 2.87% the day after the announcement, and continuing to decline to a new low of 13.47 HKD by February 12 [4][10]. - The stock has experienced a maximum fluctuation of over 30% since reaching a peak of 20.49 HKD in early November [4]. Strategic Insights - The growth in profits is attributed to the gradual release of growth potential following the inclusion of various product lines in centralized procurement, alongside the company's ongoing international development strategy [5][18]. - The overseas revenue contribution reached 40% in the first half of the previous year, indicating a strong focus on international market expansion [18]. Valuation Perspective - Following a three-month decline in stock price, Spring Medical's overall valuation has fallen below the industry average, with a current PE ratio of 19.12, compared to the industry average of 20.48 [11]. - The stock is considered undervalued, which typically attracts interest from investors looking for quality stocks at lower prices [11][13]. Investor Behavior - Recent data indicates a shift in the behavior of Hong Kong Stock Connect funds, which have transitioned from being net buyers to net sellers of Spring Medical shares [13][15]. - The holding ratio of Hong Kong Stock Connect funds peaked at 47.77% but has since dropped to 43.16%, reflecting a change in investment strategy towards trend-based trading [15][18].

Core Viewpoint - Spring Medical (01858) has announced a significant increase in its expected net profit for the fiscal year 2025, with projections indicating a rise of 96.01% to 130.41% year-on-year, driven by improvements in its core business and international expansion efforts [1][4]. Financial Performance - The company anticipates a net profit attributable to shareholders of between 245 million to 288 million yuan for 2025, and a non-recurring net profit of 230 million to 270 million yuan, reflecting increases of 96.01% to 130.41% and 142.80% to 185.11% respectively [1][4]. - In Q1 of the previous year, Spring Medical reported a revenue of 230 million yuan, marking a 3.6% increase, and a net profit of 58 million yuan, up 5.2% [7]. - By Q3 of the previous year, the company achieved a revenue of 756 million yuan, a year-on-year growth of 48.75%, and a net profit of 192 million yuan, a significant increase of 213.21% [7]. Market Reaction - Despite the positive earnings forecast, the market response has been muted, with the stock price declining by 2.87% the day after the announcement and continuing to fall, reaching a low of 13.47 HKD [4][10]. - The stock has experienced a maximum fluctuation of over 30% since hitting a peak of 20.49 HKD in early November [4][10]. Business Drivers - The growth in profits is attributed to the gradual release of growth potential following the inclusion of various product lines in centralized procurement, alongside the company's ongoing international development strategy [5][18]. - The overseas revenue contribution reached 40% in the first half of the previous year, indicating a strong international market presence [18]. Valuation - Following a three-month decline in stock price, Spring Medical's overall valuation has fallen below the industry average, with a current PE ratio of 19.12, compared to the industry average of 20.48 [11]. - The stock is considered undervalued, with a 6% lower PE ratio than its average over the past three months [11]. Investor Sentiment - Recent data indicates that the Hong Kong Stock Connect funds have shifted from being net buyers to net sellers of Spring Medical shares, with significant sell-offs observed [13][15]. - The holding ratio of Hong Kong Stock Connect funds decreased from a peak of 47.77% to 43.16%, reflecting a change in investment strategy towards trend-based trading [15].

Core Viewpoint - Southbound funds increased their holdings in Chuangli Medical (01858.HK) by 61,000 shares on February 13, 2023, despite a net reduction of 338,800 shares over the past five trading days [1] Group 1: Southbound Fund Activity - In the last five trading days, there were three days of net reductions in holdings by southbound funds, totaling 338,800 shares [1] - Over the past 20 trading days, there were ten days of net reductions, amounting to 246,800 shares [1] - As of now, southbound funds hold 41,125,800 shares of Chuangli Medical, representing 43.21% of the company's issued ordinary shares [1] Group 2: Company Overview - Beijing Chuangli Zhengda Medical Device Co., Ltd. primarily engages in the research, development, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover four major human joints: hip, knee, shoulder, and elbow, with products sold in both domestic and international markets [1]

Summary of Conference Call Notes Company and Industry Overview - The analysis focuses on Wangsu Technology (网宿科技), a CDN (Content Delivery Network) service provider, and its potential in the AI era, particularly in the context of the Agent Internet. The company is viewed as undervalued in the market [1][2]. Key Points and Arguments 1. **Company Positioning and Comparables**: - Wangsu Technology is compared to Cloudflare, highlighting similar business structures focused on acceleration (70%) and security (30%) [2][3]. - The strategic positioning of Cloudflare as a "Global Control Plane for the Agent's Internet" is praised and deemed applicable to Wangsu, providing a clear development blueprint [3]. 2. **Industry and Company Status Shift**: - **Historical Challenges**: - Wangsu faced declining market share due to competition from major cloud providers like Alibaba Cloud and Tencent Cloud, leading to a negative perception of the industry characterized by fierce price wars and poor operational conditions [3]. - **Current Improvements**: - The CDN market has stabilized, with Wangsu holding approximately 10%-20% market share, benefiting from the exit of foreign competitors like Akamai from the Chinese market [3]. 3. **Price and Volume Recovery**: - A turning point in 2024 is noted, with CDN prices not only stabilizing but beginning to rise (e.g., Google prices doubling, domestic increases of 30%-40%) [4]. - Given that hardware costs constitute only about 10% of CDN expenses, the price increases are expected to significantly enhance profitability [4]. 4. **Impact of the AI Era**: - The demand for CDN services is projected to surge due to increased interaction frequencies in the AI Agent era, where a single user request can trigger multiple interactions, necessitating ultra-low latency [5][6]. - The shift from traditional content distribution to highly personalized content delivery is expected to increase CDN traffic demands [5]. 5. **Emerging Challenges and Opportunities**: - New issues such as Skills security, authorization management, and inter-Agent communication are emerging, which Wangsu and Cloudflare's security services can address, creating a second growth curve for their businesses [4]. 6. **Market Potential and Projections**: - Future estimates suggest that the number of AI Agents will exceed the current 5 billion daily active apps, leading to explosive growth in the CDN acceleration market [4]. 7. **Company's Financial Health**: - Wangsu is reported to have 7 billion in cash, positioning it well to capitalize on AI opportunities. The company has also completed equity incentives, boosting team morale [7]. 8. **Core Conclusion and Investment Perspective**: - Wangsu Technology is at a pivotal point, transitioning from a historically perceived outdated company to a core infrastructure provider in the AI era. The company is expected to benefit from the end of adverse industry cycles, a favorable pricing environment, and new growth opportunities from the AI revolution [8][9]. 9. **Comparative Analysis**: - The company is likened to a "shovel seller" in the AI era, indicating a strong investment recommendation. It is noted that while Chinese companies have matched U.S. counterparts in technology, they still lag in strategic communication and market storytelling [9]. Additional Important Insights - The analysis emphasizes the importance of understanding the evolving landscape of the CDN market and the implications of AI on service demand, which could lead to significant investment opportunities in Wangsu Technology [4][8].

Core Viewpoint - The company has successfully integrated multiple cutting-edge intelligent technologies into its surgical robots, which are now in mass production [1] Group 1: Product Development - The company has obtained registration certificates for hip joint surgical robots, knee joint surgical robots, and unicompartmental surgical robots [1] - The products form a comprehensive digital orthopedic solution covering preoperative, intraoperative, and postoperative stages [1] Group 2: International Business Strategy - The company is actively responding to the national "Belt and Road" initiative and is steadily advancing its international business layout [1]

Core Viewpoint - The recent issuance of the "Guidelines for the Project Establishment of Surgical and Treatment Auxiliary Medical Service Price Items (Trial)" by the National Medical Insurance Administration aligns with the company's surgical robot business, which has successfully obtained registration certificates for various orthopedic surgical robots [1] Group 1: Company Developments - The company has developed a comprehensive digital orthopedic solution covering pre-operative, intra-operative, and post-operative stages with its surgical robots [1] - The company has successfully registered products including hip joint surgical robots, knee joint surgical robots, and unicompartmental surgical robots [1] Group 2: Industry Trends - The new policy aims to standardize pricing for surgical robots and remote surgeries, indicating a growing recognition and support for advanced medical technologies in the healthcare sector [1] - The company is actively responding to the national "Belt and Road" initiative, steadily advancing its international business layout [1]